TEL AVIV, Israel, November 16, 2017 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX.TA), a clinical-stage
biopharmaceutical company focused on oncology and immunology,
announced today that it will host an investor breakfast meeting on
Tuesday, December 5, 2017 at the
Convene Conference Center near Grand Central in New York, NY.
The agenda and topics for discussion include: (i) a keynote
presentation by Dr. John F.
DiPersio, Chief, Division of Oncology at Washington University School of Medicine, on bone
marrow transplantation and the role of CXCR4 in cancer; (ii)
presentation on BL-8040 development plans in immuno-oncology
combinations, as well as on the upcoming GENESIS Phase 3 study in
stem cell mobilization for autologous bone-marrow transplantation
in multiple myeloma patients; (iii) presentation of AGI-134, the
Company's novel immuno-oncology project; and (iv) an overview of
the Company's plans and expected milestones for 2018.
The investor meeting schedule is as follows:
- 8:30 am EST - Registration
- 9:00-10:30 am EST - Formal
Presentations and Q&A
Location:
Convene Conference Center
101 Park Avenue near Grand Central
New York, NY
888-730-7307
BioLineRx Ltd. will also host a live audio webcast of the
investor breakfast. To access the webcast, please go to the
breakfast event page on BioLineRx's website. It is recommended that
users register 15 minutes prior to the scheduled start time to
ensure timely connection. An audio replay of the meeting will also
be available for approximately three months following the meeting
on the breakfast event page.
Registration and Additional Information
Advanced registration is required for onsite attendance. To
register, please contact Vivian
Cervantes at vivian@pcgadvisory.com.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company focused
on oncology and immunology. The Company in-licenses novel
compounds, develops them through pre-clinical and/or clinical
stages, and then partners with pharmaceutical companies for
advanced clinical development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
cancer therapy platform, which has successfully completed a Phase
2a study for relapsed/refractory AML, is in the midst of a Phase 2b
study as an AML consolidation treatment and is expected to initiate
a Phase 3 study in stem cell mobilization for autologous
transplantation; and AGI-134, an immunotherapy treatment in
development for multiple solid tumors, which is expected to
initiate a first-in-man study in the first half of 2018. In
addition, BioLineRx has a strategic collaboration with Novartis for
the co-development of selected Israeli-sourced novel drug
candidates; a collaboration agreement with MSD (known as Merck in
the US and Canada), on the basis
of which the Company has initiated a Phase 2a study in pancreatic
cancer using the combination of BL-8040 and Merck's
KEYTRUDA®; and a collaboration agreement with Genentech,
a member of the Roche Group, to investigate the combination of
BL-8040 and Genentech's atezolizumab in several Phase 1b/2 studies
for multiple solid tumor indications and AML.
For additional information on BioLineRx, please visit the
Company's website at http://www.biolinerx.com, where you can review
the Company's SEC filings, press releases, announcements and
events. BioLineRx industry updates are also regularly updated on
Facebook, Twitter, and LinkedIn.
Various statements in this release concerning
BioLineRx's future expectations constitute
"forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements include words such as
"may," "expects,"
"anticipates,"
"believes," and
"intends," and describe opinions about
future events. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the actual results,
performance or achievements of BioLineRx to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these risks
are: changes in relationships with collaborators; the impact of
competitive products and technological changes; risks relating to
the development of new products; and the ability to implement
technological improvements. These and other factors are more fully
discussed in the "Risk Factors" section
of BioLineRx's most recent annual report on Form 20-F
filed with the Securities and Exchange Commission on March 23, 2017. In addition, any forward-looking
statements represent BioLineRx's views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. BioLineRx does not assume any
obligation to update any forward-looking statements unless required
by law.
Contacts:
PCG Advisory
Vivian Cervantes
Investor Relations
+1-212-554-5482
vivian@pcgadvisory.com
or
Tsipi Haitovsky
Public Relations
+972-52-989892
tsipihai5@gmail.com
SOURCE BioLineRx Ltd.